Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information

Hong Yang1,2,†, Chu Qin1,†, Ying Hong Li2,†, Lin Tao1, Jin Zhou2, Chun Yan Yu2, Feng Xu3, Zhe Chen4, Feng Zhu1,2,* and Yu Zong Chen1,*

1Bioinformatics and Drug Design Group, Department of Pharmacy, and Center for Computational Science and Engineering, National University of Singapore, 117543, Singapore, 2Innovative Drug Research Centre and College of Chemistry and Chemical Engineering, Chongqing University, Chongqing 401331, P. R. China, 3College of Pharmacy, State Key Laboratory of Medicinal Chemical Biology and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, P. R. China and 4Zhejiang Key Laboratory of Gastro-intestinal Pathophysiology, Zhejiang Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University, No. 54 Youdian Road, Hangzhou 310006, China

Received September 19, 2015; Revised October 27, 2015; Accepted October 30, 2015

ABSTRACT

Extensive drug discovery efforts have yielded many approved and candidate drugs targeting various targets in different biological pathways. Several freely accessible databases provide the drug, target and drug-targeted pathway information for facilitating drug discovery efforts, but there is an insufficient coverage of the clinical trial drugs and the drug-targeted pathways. Here, we describe an update of the Therapeutic Target Database (TTD) previously featured in NAR. The updated contents include: (i) significantly increased coverage of the clinical trial targets and drugs (1.6 and 2.3 times of the previous release, respectively), (ii) cross-links of most TTD target and drug entries to the corresponding pathway entries of KEGG, MetaCyc/BioCyc, NetPath, PANTHER pathway, Pathway Interaction Database (PID), PathWhiz, Reactome and WikiPathways, (iii) the convenient access of the multiple targets and drugs cross-linked to each of these pathway entries and (iv) the recently emerged approved and investigational drugs. This update makes TTD a more useful resource to complement other databases for facilitating the drug discovery efforts. TTD is accessible at http://bidd.nus.edu.sg/group/ttd/ttd.asp.

INTRODUCTION

The modern drug development efforts (1–3) have led to the discovery and clinical testing of thousands of targeted agents, and the approval of a considerable number of drugs. These agents produce their therapeutic effects by modulating various targets in different biological and disease regulatory pathways. The knowledge of these agents, their efficacy targets and the targeted pathways is useful not only for the discovery and development of targeted therapeutics (4,5), but also for facilitating the research and development of systems pharmacology (6,7) aimed at the discovery of multitarget drugs (8) and drug combinations (9). Moreover, the relevant knowledge is useful for the further development and improvement of the tools used in the research and discovery of drugs, targets and system pharmacology.

While the comprehensive drug, target and drug-targeted pathway information is freely available in the established drug (10), efficacy target (11), pharmacology (12), bioactive compound (13), binding (14) and pathway (15) databases, there is an inadequate coverage of the number and the detailed information of the clinical trial drugs in these databases. As of August 2015, the number of explicitly labelled clinical trial drugs in these databases are 1130 (10), 3147 (11), 493 (12), 676 (13), 0 (14) and 0 (15), which is significantly less than that of current and discontinued clinical trial drugs (more than 9,528, as estimated in this study) searchable from the literature, public reports and clinical trial websites. The inadequate coverage of the clinical trial drugs in these databases can be further revealed by the analysis of their drug contents with respect to the reported drug clinical trial success rates. For instance, among these

*To whom correspondence should be addressed. Tel: +86 23 6567 8468; Fax: +86 23 6567 8450; Email: zhufeng@cqu.edu.cn
Correspondence may also be addressed to Yu Zong Chen. Tel: +65 6516 6877; Fax: +65 6774 6756; Email: csccyz@nus.edu.sg
†These authors contributed equally to this work as first authors.

© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
databases, the previous version of the Therapeutic Target Database (TTD) (11) contains the largest set of 3147 clinical trial drugs versus 2003 approved drugs. The ratio of the approved and clinical trial drugs is 63.6%, which is much larger than the reported 6.6–13.4% Phase I clinical trial to drug approval success rates (16,17), indicating the inadequate coverage of clinical trial drugs and targets in TTD.

There is also a lack of the coverage of the biological or disease regulatory pathways targeted by the clinical trial and investigative drugs. Moreover, while the drug-regulated pathway information may be obtained via the hyperlinks provided in some of these databases or by using the target gene ID to search the pathway databases, it is inconvenient to access the multiple drugs and targets involved in the regulation of the individual pathways. A substantial number of multitarget drugs produce their therapeutic effects via activities against multiple targets of the same pathway (18), and many drug combinations achieve synergistic therapeutic effects by modulating multiple targets in the same pathway (9). Therefore, a facility for the convenient access of the multiple targets and drugs involved in the regulation of individual pathways is highly useful for studying the mechanisms of multitarget and drug combination therapeutics.

To provide more comprehensive information about the clinical trial drugs, targets and pathways, and more convenient access of the targets and drugs associated with specific pathways, we made several major improvements to the TTD (http://bidd.nus.edu.sg/group/ttd/ttd.asp). The first is the significantly expanded coverage of the clinical trial targets and drugs to 723 targets and 9528 drugs. The second is the cross-linking of most of the TTD target and drug entries to the corresponding pathway entries of KEGG (15), MetaCyc/BioCyc (19), NetPath (20), PANTHER pathway (21), PathWhiz (22), Pathway Interaction Database (PID) (23), Reactome (24) and WikiPathways (25). Overall, 382 successful, 721 clinical trial and 330 research targets and 1144 approved, 4462 clinical trial, (including discontinued clinical trial drugs) and 14 065 investigative drugs (including preclinical drugs and drugs terminated at unspecified test stages) were cross-linked to their corresponding pathway entries. Each of these pathway entries typically contains the members of the pathway and some of the key regulators and downstream effectors (15,19–25). Therefore, the targets and drugs cross-linked to each pathway may play some roles in the regulation of the pathway or the activities of its effectors. The third is the convenient access of the multiple targets and drugs associated with each of the 302 KEGG, 211 MetaCyc/BioCyc, 26 NetPath, 134 PANTHER pathway, 99 PathWhiz, 222 PID, 578 Reactome and 524 WikiPathways pathway entries. Moreover, we added recently emerged, approved and investigative drug data to increase the TTD content to 397 successful and 1469 research targets, and 2071 approved and 17 803 investigative drugs, respectively. The statistics of our updated data is summarized in Table 1.

**CLINICAL TRIAL DRUGS AND TARGETS**

Clinical trial drugs represent special classes of therapeutic agents in advanced development stages, the knowledge of these drugs, their targets and the targeted pathways is very important for facilitating the future drug discovery efforts. Hence, there is a particular need to expand the coverage of the clinical trial drugs, targets and the targeted pathways. The clinical trial drugs and their efficacy targets were searched by the following procedure. First, we searched the PhRMA medicines in the 2009–2014 development reports and the 2014–2015 drug pipeline reports from the websites and annual reports of 183 companies. We then evaluated some of the clinical trial drugs in the earlier (2004–2010) versions of several commercial databases against the publicly accessible literature, company reports and company announcements to select those drugs reported in the public sources. The sources of the collected drugs are provided in Supplementary Table S1. For all the newly and previously collected drugs, we searched their synonyms or alternative names, removed the duplicates and further checked their clinical trial against the records in the ClinicalTrials.gov results database (26), company reports and company announcements. This procedure gave rise to 9528 drugs. These drugs were further divided into two groups, one without and the other with a report of the drug being discontinued in clinical trials in the publicly accessible literature or public announcements. The clinical phase of these drugs has been frequently provided in these multiple sources, which was recorded. For a drug with multiple clinical trial phase records, the highest phase was regarded as its clinical phase regardless of whether or not it has been discontinued in clinical trials.

The target of each drug was determined by the following procedure. For the drugs with a single target reported in these sources, each target was tentatively regarded as the efficacy target of the respective drug. For those drugs without target information or with more than one target (including different targets of the same drug reported in different sources), we conducted additional literature search for finding or verifying their efficacy targets linked to the clinically tested therapeutics using the established criterion of efficacy targets (27) that we have used in the development of the TTD database (28). An efficacy target is defined (27) as a protein, DNA, RNA or membrane component unambiguously involved in the initiation or progression of a disease, directly modulated by a therapeutic agent at sufficient levels of potency that is typically <500 nM (ideally <100 nM) in biochemical assays (in some cases, drugs of μM potencies may show adequate potencies in cell-based, in vivo and clinical studies), and the claimed therapeutic activities have been further confirmed by additional biochemical assay and strong cell-based and in vivo studies linking the target to the drug action. For each target, its drug with the highest clinical phase was considered as the clinical phase of the target.

**THE DRUG REGULATED PATHWAYS AND THE CROSS-LINKING OF THE TTD ENTRIES TO THE ENTRIES OF THE PUBIC PATHWAY DATABASES**

Drug action depends not only on the direct modulation of its target but also on other regulatory factors and the activities of the effectors of the complex biological networks and physiological systems (29). Advances in systems biology and bioinformatics have revealed some of these mechanisms at the network and physiological levels (9,30–33),
Table 1. Statistics of the targets, drugs and the cross-linked pathway entries in 2016 update of the TTD database

| Statistics of therapeutic targets |       | 2016 update | 2014 update |
|-----------------------------------|-------|-------------|-------------|
| Number of all targets             | 2589  | 1959        |
| Number of successful targets      | 397   | 388         |
| Number of clinical trial targets  | 723   | 461         |
| Number of research targets        | 1469  | 1110        |

| Statistics of drugs               |       | 2016 update | 2014 update |
|-----------------------------------|-------|-------------|-------------|
| Number of all drugs               | 31 614| 20 667      |
| Number of approved drugs          | 2071  | 2003        |
| Number of clinical trial         | 7291  | 3147        |
| Number of drugs withdrawn from    | 2337  | 498         |
| market                           | 154   | 0           |
| Number of drugs discontinued in   | 357   | 163         |
| clinical trial                   | 1701  | 0           |
| Number of preclinical drugs       | 17 803| 14 856      |
| Number of investigative drugs     | 26 368| 20 818      |
| Number of multitarget agents      | 115   | 115         |
| Number of drug combinations       | 115   | 115         |

| Statistics of targets linked to    |       | 2016 update | 2014 update |
| their corresponding pathway entries|       | KEGG        |             |
|                                   |       | 248–191     | 0–0         |
|                                   | Metacyc/Biocys | 52–92    | 0–0         |
|                                   | Netpath        | 126–22    | 0–0         |
|                                   | PATHWAY       | 148–89    | 0–0         |
|                                   | PANTHER       | 115–71    | 0–0         |
|                                   | PID           | 132–176   | 0–0         |
|                                   | Reactome       | 312–352   | 0–0         |
|                                   | WikiPathways   | 341–392   | 0–0         |

| Statistics of drugs linked to their |       | 2016 update | 2014 update |
| corresponding pathway entries      |       | KEGG        |             |
|                                   |       | 863–191     | 0–0         |
|                                   | Metacyc/Biocys | 148–97    | 0–0         |
|                                   | Netpath        | 409–22    | 0–0         |
|                                   | PATHWAY       | 646–93    | 0–0         |
|                                   | PANTHER       | 463–69    | 0–0         |
|                                   | PID           | 454–178   | 0–0         |
|                                   | Reactome       | 974–354   | 0–0         |
|                                   | WikiPathways   | 1140–395  | 0–0         |

*The number of research targets in the 2014 release is revised from that reported in the previous publication because of removal of redundant target entries.
which open more opportunities for the development of new polypharmacology strategies in the more effective treatment of the diseases (29,34). These coupled with the knowledge of drug-regulated pathways, including those of the clinical trial and investigative drugs as well as those of the approved drugs, are highly useful for facilitating the development of the novel polypharmacology-based drug discovery.

Moreover, a number of clinically used and tested drugs target multiple targets in the same pathway (e.g. Lapatinib, Afatinib, Dacomitinib and Neratinib inhibiting EGFR and HER2 in ErbB pathway, BEZ-235, XL-765, GDC-0980 and PF-05212384 inhibiting mTOR and PI3K in PI3K/Akt/mTOR pathway and CKI-27, RO-5126766, RG7304 and RG7388 inhibiting Raf and Mek in MAPK/ERK pathway) (18). One of the main mode of actions of the synergistic drug combinations is related to the modulation of multiple targets in the same pathway (9). Therefore, the information of the targets in and the drugs against the same pathway is highly useful for facilitating the discovery and the studies of the mechanisms of multitarget and drug combination therapeutics.

A number of targets can be found in the pathway entries of public pathway databases such as KEGG (15), MetaCyc/BioCyc (19), NetPath (20), PANTHER pathway (21), PathWhiz (22), PID (23), Reactome (24) and WikiPathways (25) databases. These targets may be the members, regulators or effectors of the biological networks in these pathway entries. Drug actions against some of these targets may have thus some effect on the activities of the respective pathways, and the cross-linking of the targets and drugs to their respective pathway entries may facilitate the discovery (29,34) and studies (9,30–33) of drugs, multitarget agents and drug combinations from the pathway regulation perspectives.

The cross-links of targets and drugs to the respective pathway entries were established by the following procedure. We firstly searched Uniprot database (35) to obtain the Uniprot ID of every target, from which each target and its drugs were directly linked via Uniprot cross-links to the corresponding KEGG (15) pathway entry or entries. We then mapped the Uniprot ID of every target to those of the members of the PANTHER pathway, PathWiz database, PID, Reactome and WikiPathways pathway entries. The cross-links of each target and its drugs to the corresponding members of the MetaCyc/BioCyc, NetPath and WikiPathways entries were established based on the match of the target’s gene name with those in the gene name list of the respective pathway entries. Overall, we were able to link 381 successful targets and 1144 approved drugs, 721 targets and 4694 drugs in clinical trials, and 326 targets and 14 065 drugs in investigative stages to 302 KEGG, 211 MetaCyc/BioCyc, 26 NetPath, 134 PANTHER pathway, 99 PathWhiz, 222 PID, 578 Reactome and 524 WikiPathways pathway entries, respectively.

ILLUSTRATIVE EXAMPLES OF THE SEARCH OF A TARGET, A DRUG AND THE CROSS-LINKED PATHWAY ENTRIES

A user can search for the information of a target in the ‘Search for targets’ field of the TTD homepage by inputting keywords such as a target name ‘Glucokinase’ and then clicking the ‘Search’ button on the right-hand side, which leads to the particular target page (Supplementary Figure S1), wherein, the user can find the information about the target type (in this case clinical trial target), synonyms, targeted diseases, biochemical class (in this case kinase), the function, drugs and the pathway entries of which the target is a member, regulator or effector. In the ‘Drug(s)’ section, a user can click the ‘Drug Info’ button behind each drug name to access the respective TTD drug page described below.

One may search for the information of a drug in the ‘Search for drugs’ field in the TTD homepage by inputting keywords such as a drug name ‘Buparlisib’, and then clicking the ‘Search’ button on the right-hand side, which leads to the particular drug page (Supplementary Figure S2), wherein the user can obtain the information about the drug structure (2D, 3D, InChI, InChIKey and SMILES), the drug-making company (in this case Novartis), the disease indication (disease and the corresponding international disease ICD9 and ICD10 codes), the drug status (in this case Phase III), the Pubchem compound ID, the Pubchem substance ID and its targets (in this case PI3K alpha, beta, gamma and delta). In the structure section, one can download the 2D or 3D structure of the drug by right-clicking the 2D-Mol or 3D-Mol link, respectively. In the ‘Target’ section, one can click the ‘Target Info’ button to access the respective TTD target page described above.

A pathway search page was introduced for accessing the pathway entries cross-linked to a specific target or drug and for finding the targets or drugs cross-linked to the same user-selected pathway entry. This page (Figure 1) is accessible by clicking the ‘Pathway Search’ button in the upper right corner of the TTD homepage. The upper part of the page is the ‘Search Cross-Linked Pathway Entries’ field, wherein, the user can search the pathway entries cross-linked to individual targets and drugs by inputting a specific target name (e.g. Glucokinase) or drug name (e.g. Buparlisib) in the ‘Search Cross-Linked Pathway Entries by Target Name’ or ‘Search Cross-Linked Pathway Entries by Drug Name’ sub-field followed by the click of the ‘Search’ button in the respective search sub-field, which leads to the pathway entries cross-linked to the target (Supplementary Figure S3) or the drug (Supplementary Figure S4). The lower part is the ‘Search Targets and Drugs Cross-Linked to the Same Pathway Entry’ field, wherein, the user can search the targets and drugs cross-linked to the same pathway entries of a specific pathway database by clicking on the button of a particular pathway database (e.g. KEGG) followed by the selection of the particular pathway entry (e.g. Thyroid hormone synthesis) in the pathway entries manual, which leads to the page showing the list of targets (Supplementary Figure S5) or the drugs (Supplementary Figure S6) cross-linked to the same user-selected pathway entry.

CONCLUDING REMARKS

The need for improved drug discovery productivity (36,37) has led to intensifying efforts in drug discovery by employing advanced technologies (1–3), novel therapeutic strategies such as polypharmacology (6,7), monoclonal antibod-
ies (38) and RNA therapeutics (39), and the knowledge of the drug-like properties (40), target druggability features, and the systems-level profiles (9,30–33) learned from the studies of the approved and clinical trial drugs and targets. The enriched information and search facilities in TTD complements the other established drug (10) and pathway (15,19–25) databases for providing the comprehensive information about the drugs, targets and the targeted pathways in facilitating the research and drug discovery efforts.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.

FUNDING
National Natural Science Foundation of China [81202459]; Singapore Academic Research Fund [R-148-000-208-112]; Natural Science Foundation Project of CQ CSTC [cstc2012jjA10116]; Fundamental Research Funds for the Central Universities [CQDXWL-2012-Z003, CDJZR14468801, CDJKX14011, 2015CDJXY]. Funding for open access charge: National Natural Science Foundation of China [81202459]; Singapore Academic Research Fund [R-148-000-208-112]; Natural Science Foundation Project of CQ CSTC [cstc2012jjA10116]; Fundamental Research Funds for the Central Universities [CQDXWL-2012-Z003, CDJZR14468801, CDJKX14011, 2015CDJXY].

Conflict of interest statement. None declared.
REFERENCES

1. Hopkins,A.L. and Groom,C.R. (2002) The druggable genome. *Nat. Rev. Drug Discov.*, 1, 727–730.
2. Imming,P., Sinning,C. and Meyer,A. (2006) Drugs, their targets and the nature and number of drug targets. *Nat. Rev. Drug Discov.*, 5, 821–834.
3. Zheng,C.J., Han,L.Y., Yap,C.W., Ji,Z.L., Cao,Z.W. and Chen,Y.Z. (2006) Therapeutic targets: progress of their exploration and investigation of their characteristics. *Pharmacol. Res.*, 58, 259–279.
4. Engelman,J.A., Zeinullahu,K., Mitsudomi,T., Song,Y., Hyland,C., Park,J.O., Lindeman,N., Gale,C.M., Zhao,X., Christensen,J. et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*, 316, 1039–1043.
5. Chen,Z., Cheng,K., Walton,Z., Wang,Y., Ebi,H., Shimamura,T., Liu,Y., Tupper,T., Ouyang,J., Li,J. et al. (2012) A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. *Nature*, 483, 613–617.
6. Barabasi,A.L., Gulbahce,N. and Loscalzo,J. (2011) Network medicine: a network-based approach to human disease. *Nat. Rev. Genet.*, 12, 56–68.
7. Zhao,S. and Iyengar,R. (2012) Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. *Annu. Rev. Pharmacol. Toxicol.*, 52, 505–521.
8. Csermely,P., Agoston,V. and Pongor,S. (2005) The efficiency of multi-target drugs: the network approach might help drug design. *Trends Pharmacol. Sci.*, 26, 178–182.
9. Jia,J., Zhu,F., Ma,X., Cao,Z., Li,Y. and Chen,Y.Z. (2009) Mechanisms of drug combinations: interaction and network perspectives. *Nat. Rev. Drug Discov.*, 8, 111–128.
10. Law,V., Knox,C., Djoumbou,Y., Jewison,T., Guo,A.C., Liu,Y., Maciejewski,A., Arndt,D., Wilson,M., Neveu,V. et al. (2014) DrugBank 4.0: shedding new light on drug metabolism. *Nucleic Acids Res.*, 42, D1091–D1107.
11. Qin,C., Zhang,C., Zhu,F., Xu,F., Chen,S.Y., Zhang,P., Li,Y.H., Yang,S.Y., Wei,Y.Q., Tao,L. et al. (2014) Therapeutic target database update 2014: a resource for targeted therapeutics. *Nucleic Acids Res.*, 42, D1118–D1123.
12. Pawson,A.J., Sharman,J.L., Benson,H.E., Facenda,E., Alexander,S.P., Buneman,O.P., Davenport,A.P., McGrath,J.C., Peters,J.A., Southam,C. et al. (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. *Nucleic Acids Res.*, 42, D1098–D1106.
13. Bento,A.P., Gautlon,A., Hersey,A., Bellis,L.J., Chambers,J., Davies,M., Kruger,F.A., Light,Y., Mak,L., McGlinchey,S., et al. (2014) The ChEMBL bioactivity database: an update. *Nucleic Acids Res.*, 42, D1083–D1090.
14. Liu,T., Lin,Y., Wen,X., Joissen,R.N. and Gilson,M.K. (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. *Nucleic Acids Res.*, 35, D198–D201.
15. Kanehisa,M., Goto,S., Sato,Y., Kawashima,M., Furumichi,M. and Tanabe,M. (2014) Data, information, knowledge and principle: back to metabolism in KEGG. *Nucleic Acids Res.*, 42, D199–D205.
16. Bunnage,M.E. (2011) Getting pharmaceutical R&D back on target. *Nat. Chem. Biol.*, 7, 335–339.
17. DiMasi,J.A., Reichert,J.M., Feldman,L. and Malins,A. (2013) Clinical approval success rates for investigational cancer drugs. *Clin. Pharmacol. Ther.*, 94, 329–335.
18. Tao,L., Zhu,F., Xu,F., Chen,Z., Jiang,Y. and Chen,Y. (2015) Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. *Pharmacol. Res.*, In press.
19. Caspi,R., Altman,T., Billington,R., Dreher,K., Foerster,H., Fulcher,C.A., Holland,T.A., Keseler,I.M., Kothari,A., Kubo,A. et al. (2014) The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. *Nucleic Acids Res.*, 42, D459–D471.
20. Kandasamy,K., Mohan,S.S., Raju,R., Keerthikumar,S., Kumar,G.S., Venugopal,A.K., Telikicherla,D., Navarro,J.D., Mathivanan,S., Pecquet,C. et al. (2010) NetPath: a public resource of curated signal transduction pathways. *Genome Biol.*, 11, R3.
21. Mi,H. and Thomas,P. (2009) PANTHER pathway: an ontology-based pathway database coupled with data analysis tools. *Methods Mol. Biol.*, 563, 123–140.
22. Pan,A., Jewison,T., Su,Y., Liang,Y., Knox,C., Maciejewski,A., Wilson,M. and Wishart,D.S. (2015) Pathways with PathWhiz. *Nucleic Acids Res.*, 43, W552–W559.
23. Schaefer,C.F., Anthony,K., Krupa,S., Buchhoff,J., Day,M., Hannay,T. and Buettow,K. (2009) PID: the pathway interaction database. *Nucleic Acids Res.*, 37, D674–D679.
24. Croft,D., O’Kelly,G., Wu,G., Haw,R., Gillespie,M., Matthews,L., Caudy,M., Garapati,P., Gopinath,G., Jassal,B. et al. (2011) Reactome: a database of reactions, pathways and biological processes. *Nucleic Acids Res.*, 39, D691–D697.
25. Kelder,T., van Iersel,M.P., Hanspers,K., Kutmon,M., Conklin,B.R., Evelo,C.T. and Pico,A.R. (2012) WikiPathways: building research communities on biological pathways. *Nucleic Acids Res.*, 40, D1301–D1307.
26. Zarin,D.A., Tse,T., Williams,R.J., Califf,R.M. and Ide,N.C. (2011) The ClinicalTrials.gov results database-update and key issues. *N. Engl. J. Med.*, 364, 852–860.
27. Overington,J.P., Al-Lazikani,B. and Hopkins,A.L. (2006) How many drug targets are there? *Nat. Rev. Drug Discov.*, 5, 993–996.
28. Zhu,F., Shi,Z., Qin,C., Tao,L., Liu,X., Xu,F., Zhang,L., Song,Y., Liu,X., Zhang,J. et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. *Nucleic Acids Res.*, 40, D1128–D1136.
29. Berg,J.M., Rogers,M.E. and Lyster,P.M. (2010) Systems biology and pharmacology. *Clin. Pharmacol. Ther.*, 88, 17–19.
30. Barabasi,A.L. and Otvalt,Z.N. (2004) Network biology: understanding the cell’s functional organization. *Nat. Rev. Genet.*, 5, 101–113.
31. Yao,L. and Rzhetsky,A. (2008) Quantitative systems-level determinants of human genes targeted by successful drugs. *Genome Res.*, 18, 206–213.
32. Zhu,F., Han,L., Zheng,C., Xie,B., Tammi,M.T., Yang,S., Wei,Y. and Chen,Y. (2009) What are next generation innovative therapeutic targets? Clues from genetic, structural, physiochemical, and systems profiles of successful targets. *J. Pharmacol. Exp. Ther.*, 330, 304–315.
33. Zhang,J., Jia,J., Zhu,F., Ma,X., Han,B., Wei,X., Tan,C., Jiang,Y. and Chen,Y. (2012) Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. *Mol. Biosyst.*, 8, 2645–2656.
34. Hopkins,A.L. (2008) Network pharmacology: the next paradigm in drug discovery. *Nat. Chem. Biol.*, 4, 682–690.
35. The UniProt Consortium. (2015) UniProt: a hub for protein information. *Nucleic Acids Res.*, 43, D204–D212.
36. Paul,S.M., Mytelka,D.S., Dunwiddie,C.T., Persinger,C.C., Munos,B.H., Lindborg,S.R. and Schacht,A.L. (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. *Nat. Rev. Drug Discov.*, 9, 203–214.
37. Pammolli,F., Magazzini,L. and Riccaboni,M. (2011) The productivity crisis in pharmaceutical R&D. *Nat. Rev. Drug Discov.*, 10, 428–438.
38. Nelson,A.L., Dhimolea,E. and Reichert,J.M. (2010) Development trends for human monoclonal antibody therapeutics. *Nat. Rev. Drug Discov.*, 9, 767–774.
39. Kole,R., Krainer,A.R. and Altman,S. (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. *Nat. Rev. Drug Discov.*, 11, 125–140.
40. Lipinski,C.A., Lombardo,F., Dominy,B.W. and Feeney,P.J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Res.*, 46, 3–26.